The ancient martial art of tai chi has similar or greater heath benefits than aerobic exercise for people with the chronic pain condition, fibromyalgia, finds a trial published recently by the BMJ.
Zealand Pharma A/S announced completion of patient enrollment in the second Phase III-trial, 17103, of dasiglucagon for the treatment of Congenital hyperinsulinism (CHI) in neonates up to 12 months old.
Hutchison China MediTech Limited (“Chi-Med”) announced at ASCO that results from its pivotal Phase III trial with fruquintinib, its novel...
The China regulator has approved Hutchison China MediTech’s (Chi-Med’s) second internally discovered cancer drug, surufatinib (brand name Sulanda) for the treatment of epNET (non-pancreatic [extra-pancreatic] neuroendocrine tumours).
Hutchison China MediTech Limited (�Chi-Med�) announces that fruquintinib capsules have been granted approval for drug registration by the National Medical...
Zealand Pharma A/S announced that clinical results from the two-part Phase III trial of dasiglucagon for the treatment of congenital hyperinsulinism (CHI) in newborns and infants up to 12 months of age were presented at the 60th annual European Society for Paediatric Endocrinology (ESPE) meeting, held in Rome, September 15-17, 2022
Zealand Pharma A/S announced that the FDA has granted priority review designation for dasiglucagon for the prevention and treatment of hypoglycemia in pediatric patients 7 days of age and older with CHI for up to 3 weeks of dosing. The regulatory review will be conducted in two parts under the same NDA.
Zealand Pharma A/S announced that the FDA has issued a Complete Response Letter (CRL) for Part 1 of the New Drug Application (NDA) for dasiglucagon for the prevention and treatment of hypoglycemia in pediatric patients 7 days of age and older with congenital hyperinsulinism (CHI) for up to 3 weeks of dosing
Topical treatment of moderate scalp psoriasis in adults.
Zealand Pharma A/S announced the submission of a NDA to the FDA for dasiglucagon for the prevention and treatment of low blood sugar (hypoglycemia) in pediatric patients 7 days of age or older with congenital hyperinsulinism.